Seattle Genetics, Inc.SGEN was a big mover last session, as the company saw its shares rise nearly 6% on Friday. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $53.08 -$71.80 in the past one-month time frame, witnessed a sharp increase on Friday.
The move came after the company obtained the FDA's approval for its ADCETRIS therapy along with CHP chemotherapy.
The company has seen a mixed track record when it comes to estimate revisions of one increase and five decreases in the past month, while the Zacks Consensus Estimate has also moved lower over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Seattle Genetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Seattle Genetics, Inc. Price
A better-ranked stock in the Medical - Biomedical and Genetics industry is Alexion Pharmaceuticals, Inc. ALXN , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.